181 related articles for article (PubMed ID: 34090174)
1. Nilotinib-Associated Atherosclerosis Presenting as Multifocal Intracranial Stenosis and Acute Stroke.
Kakadia B; Thakkar R; Sanborn E; Suero-Abreu GA; Jovin TG; Then R
J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105883. PubMed ID: 34090174
[TBL] [Abstract][Full Text] [Related]
2. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
[TBL] [Abstract][Full Text] [Related]
3. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
Mirault T; Rea D; Azarine A; Messas E
Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
[TBL] [Abstract][Full Text] [Related]
4. Nilotinib related acute myocardial infarction with nonobstructive coronary arteries: a case report and literature review.
Chen W; Du B; Liu K; Yu Z; Wang X; Yang P
BMC Cardiovasc Disord; 2022 Feb; 22(1):46. PubMed ID: 35152884
[TBL] [Abstract][Full Text] [Related]
5. [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].
Gautier V; Mirault T; Azarine A; Alsac JM; Sapoval M; Réa D; Messas E
J Mal Vasc; 2015 Jul; 40(4):231-9. PubMed ID: 26139550
[TBL] [Abstract][Full Text] [Related]
6. Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.
Ozaki T; Nakamura H; Izutsu N; Masaie H; Ishikawa J; Kinoshita M
Interv Neuroradiol; 2017 Oct; 23(5):527-530. PubMed ID: 28583043
[TBL] [Abstract][Full Text] [Related]
7. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
[TBL] [Abstract][Full Text] [Related]
8. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
Kim TD; Rea D; Schwarz M; Grille P; Nicolini FE; Rosti G; Levato L; Giles FJ; Dombret H; Mirault T; Labussière H; Lindhorst R; Haverkamp W; Buschmann I; Dörken B; le Coutre PD
Leukemia; 2013 Jun; 27(6):1316-21. PubMed ID: 23459449
[TBL] [Abstract][Full Text] [Related]
9. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.
Sarlon-Bartoli G; Michel Q; Sarlon E; Carcopino-Tusoli M; Suchon P; Soler R; Bartoli MA; Brunet D; Morange P; Charbonnier A
J Med Vasc; 2021 Apr; 46(2):66-71. PubMed ID: 33752848
[TBL] [Abstract][Full Text] [Related]
11. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Suh KJ; Lee JY; Shin DY; Koh Y; Bang SM; Yoon SS; Park S; Kim I; Lee JO
Int J Hematol; 2017 Aug; 106(2):229-239. PubMed ID: 28378056
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.
Petrikova L; Slezakova K; Sninska Z; Harvanova L; Martisova M; Hatalova A; Mistrik M; Batorova A; Mladosievicova B
Bratisl Lek Listy; 2021; 122(8):531-537. PubMed ID: 34282617
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
15. Clinical cardiac safety profile of nilotinib.
Kim TD; le Coutre P; Schwarz M; Grille P; Levitin M; Fateh-Moghadam S; Giles FJ; Dörken B; Haverkamp W; Köhncke C
Haematologica; 2012 Jun; 97(6):883-9. PubMed ID: 22271904
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
17. Multiple squamous cell carcinomas following introduction of nilotinib.
Peters P; Rabbolini D; Sinnya S; Khosrotehrani K; Wagner G
Clin Exp Dermatol; 2014 Oct; 39(7):791-4. PubMed ID: 25155911
[TBL] [Abstract][Full Text] [Related]
18. Acute ischemic intestinal necrosis as a rare side effect of nilotinib.
Li L; Liu W; Zeng Z; Chen S
Niger J Clin Pract; 2019 Jan; 22(1):131-133. PubMed ID: 30666032
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
Hadzijusufovic E; Albrecht-Schgoer K; Huber K; Hoermann G; Grebien F; Eisenwort G; Schgoer W; Herndlhofer S; Kaun C; Theurl M; Sperr WR; Rix U; Sadovnik I; Jilma B; Schernthaner GH; Wojta J; Wolf D; Superti-Furga G; Kirchmair R; Valent P
Leukemia; 2017 Nov; 31(11):2388-2397. PubMed ID: 28757617
[TBL] [Abstract][Full Text] [Related]
20. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
